Taking into consideration the important contribution of triggering antimyeloma immunity in disease control, we believe that the combination of anti-CD38 MoAbs with IMiDs seems to be an extremely attractive therapeutic approach, for the treatment not only of active MM, but also of smoldering MM (SMM); studies examining the efficacy of CD38 MoAbs in combination with lenalidomide for high-risk SMM are ongoing [125]. The gene discussed is CD38; the disease is Miyoshi myopathy.